349 results on '"Amaria, Rodabe N."'
Search Results
2. Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
3. Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results
4. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
5. Neoadjuvant relatlimab and nivolumab in resectable melanoma
6. Contributors
7. Melanoma
8. B cells and tertiary lymphoid structures promote immunotherapy response
9. Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression
10. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020
11. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
12. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge—December 1st–2nd, 2021
13. Coenzyme A fuels T cell anti-tumor immunity
14. Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
15. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
16. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era
17. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma
18. Project Optimus elicits the "holistic" benefits of PK/PD modeling of immunotherapy
19. Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma
20. Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
21. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
22. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
23. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
24. Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy
25. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
26. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
27. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
28. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
29. Neoadjuvant Immunotherapy for Locally Advanced Melanoma
30. Neoadjuvant Systemic Therapy for High-Risk Melanoma Patients
31. Dabrafenib in Melanoma
32. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune‐related adverse event reveal upregulation of toll‐like receptor 4/complement‐induced innate immune response and increased density ofT H 1T‐cells
33. Abstract CT107: Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
34. Supplementary Figure Legends from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
35. Supplementary Tables 1 - 11 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
36. Supplementary Figures from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
37. Supplementary Figures 1 - 13 from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
38. Supplementary Tables from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
39. Data from Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
40. Data from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
41. Supplementary Figure Legends from A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling
42. Supplementary Figure from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
43. Figures S1-S9 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
44. Supplementary Table from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma
45. Supplementary information from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
46. Supplementary Figure and Supplementary Tables from Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
47. Supplementary Table S2 from The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression
48. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy
49. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
50. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.